SAFETY DATA SHEET



Seahorse XF Hu T Cell Activation Assay Kit

Section 1. Identification

1.1 Product identifier

: Seahorse XF Hu T Cell Activation Assay Kit **Product name**

: 103759-100. 103766-100 Part no. (chemical kit)

: **2**-deoxyglucose (2-DG) 103761-000 Part no.

ImmunoCult™ Human CD3/CD28 T Cell 103760-000

Activator

: 4/29/2024 Validation date

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : For research use only.

> 2-deoxyglucose (2-DG) 2 x 246.24 mg

ImmunoCult™ Human CD3/CD28 T Cell 1 x 2 ml

Activator

: Not for use in diagnostic procedures (RUO). **Uses advised against**

1.3 Details of the supplier of the safety data sheet

Supplier/Manufacturer : Agilent Technologies, Inc.

5301 Stevens Creek Blvd Santa Clara, CA 95051, USA

800-227-9770

1.4 Emergency telephone number

In case of emergency : CHEMTREC®: 1-800-424-9300

Section 2. Hazards identification

2.1 Classification of the substance or mixture

OSHA/HCS status : **2**-deoxyglucose (2-DG) While this material is not considered hazardous by the

> OSHA Hazard Communication Standard (29 CFR 1910.1200), this SDS contains valuable information critical to the safe handling and proper use of the product. This SDS should be retained and available for employees

and other users of this product.

ImmunoCult™ Human While this material is not considered hazardous by the

CD3/CD28 T Cell Activator OSHA Hazard Communication Standard (29 CFR 1910.1200), this SDS contains valuable information

critical to the safe handling and proper use of the product. This SDS should be retained and available for employees

and other users of this product.

Classification of the substance or mixture

Not classified.

T Cell Activator

mmunoCult™ Human CD3/CD28 Percentage of the mixture consisting of ingredient (s) of unknown hazards to the aquatic environment:

1.2%

2.2 GHS label elements

Signal word : **2**-deoxyglucose (2-DG) No signal word. ImmunoCult™ Human CD3/CD28 No signal word.

T Cell Activator

Section 2. Hazards identification

Hazard statements : Z-deoxyglucose (2-DG) No known significant effects or critical hazards. ImmunoCult™ Human CD3/CD28 No known significant effects or critical hazards.

T Cell Activator

Precautionary statements

Prevention : 2-deoxyglucose (2-DG) Not applicable.

ImmunoCult™ Human CD3/CD28 Not applicable.

T Cell Activator

Response : 2-deoxyglucose (2-DG) Not applicable.

ImmunoCult™ Human CD3/CD28 Not applicable.

T Cell Activator

Storage : 2-deoxyglucose (2-DG) Not applicable.

ImmunoCult™ Human CD3/CD28 Not applicable.

T Cell Activator

ImmunoCult™ Human CD3/CD28 Not applicable.

T Cell Activator

Supplemental label : 2-deoxyglucose (2-DG)

2-deoxyglucose (2-DG) None known. ImmunoCult™ Human CD3/CD28 None known.

T Cell Activator

2.3 Other hazards

Hazards not otherwise

classified

elements

: **2**-deoxyglucose (2-DG) None known. ImmunoCult[™] Human CD3/CD28 None known.

T Cell Activator

Section 3. Composition/information on ingredients

Substance/mixture : Z-deoxyglucose (2-DG) Substance ImmunoCult™ Human CD3/CD28 T Mixture

Cell Activator

Ingredient name	%	CAS number
2-deoxyglucose (2-DG)		
2-deoxy-D-glucose	100	154-17-6

Any concentration shown as a range is to protect confidentiality or is due to batch variation.

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified and hence require reporting in this section.

Occupational exposure limits, if available, are listed in Section 8.

Section 4. First aid measures

4.1 Description of necessary first aid measures

Eye contact : 2-deoxyglucose (2-DG)

Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids.

Check for and remove any contact lenses. Get

medical attention if irritation occurs.

ImmunoCult™ Human CD3/CD28

T Cell Activator

Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.

Date of issue: 04/29/2024 **2/14**

Section 4. First aid measures

Inhalation : **2**-deoxyglucose (2-DG) Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical

attention if symptoms occur.

ImmunoCult™ Human CD3/CD28

T Cell Activator

Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48

hours.

: **2**-deoxyglucose (2-DG) **Skin contact** Flush contaminated skin with plenty of water.

Remove contaminated clothing and shoes. Get

medical attention if symptoms occur.

ImmunoCult™ Human CD3/CD28

T Cell Activator

Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get

medical attention if symptoms occur.

Ingestion : **2**-deoxyglucose (2-DG) Wash out mouth with water. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms

occur.

ImmunoCult™ Human CD3/CD28

T Cell Activator

Wash out mouth with water. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms

occur.

4.2 Most important symptoms/effects, acute and delayed

Potential acute health effects

: **2**-deoxyglucose (2-DG) Eye contact No known significant effects or critical hazards.

ImmunoCult™ Human CD3/CD28 No known significant effects or critical hazards.

T Cell Activator

: **2**-deoxyglucose (2-DG) Inhalation No known significant effects or critical hazards.

ImmunoCult™ Human CD3/CD28 No known significant effects or critical hazards.

T Cell Activator

: **2**-deoxyglucose (2-DG) Skin contact No known significant effects or critical hazards.

ImmunoCult™ Human CD3/CD28 No known significant effects or critical hazards.

T Cell Activator

: **2**-deoxyglucose (2-DG) Ingestion No known significant effects or critical hazards. No known significant effects or critical hazards.

ImmunoCult™ Human CD3/CD28

T Cell Activator

Over-exposure signs/symptoms

Eye contact : 2-deoxyglucose (2-DG) No specific data.

ImmunoCult™ Human CD3/CD28 No specific data.

T Cell Activator

: 2-deoxyglucose (2-DG) No specific data. Inhalation

ImmunoCult™ Human CD3/CD28 No specific data.

T Cell Activator

: **2**-deoxyglucose (2-DG) Skin contact No specific data.

ImmunoCult™ Human CD3/CD28 No specific data.

T Cell Activator

Ingestion : **2**-deoxyglucose (2-DG) No specific data.

ImmunoCult™ Human CD3/CD28 No specific data.

T Cell Activator

Date of issue: 04/29/2024 3/14

Section 4. First aid measures

4.3 Indication of immediate medical attention and special treatment needed, if necessary

Notes to physician : **2**-deoxyglucose (2-DG) Treat symptomatically. Contact poison treatment

specialist immediately if large quantities have been

ingested or inhaled.

ImmunoCult™ Human CD3/CD28

T Cell Activator

In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed

person may need to be kept under medical

surveillance for 48 hours.

: **2**-deoxyglucose (2-DG) **Specific treatments**

ImmunoCult™ Human CD3/CD28

T Cell Activator

No specific treatment. No specific treatment.

: **2**-deoxyglucose (2-DG)

No action shall be taken involving any personal risk

or without suitable training.

ImmunoCult™ Human CD3/CD28

T Cell Activator

No action shall be taken involving any personal risk

or without suitable training.

See toxicological information (Section 11)

Section 5. Fire-fighting measures

5.1 Extinguishing media

Protection of first-aiders

Suitable extinguishing

media

: **2**-deoxyglucose (2-DG)

Use an extinguishing agent suitable for the

surrounding fire.

ImmunoCult™ Human CD3/CD28

T Cell Activator

Use an extinguishing agent suitable for the

surrounding fire.

Unsuitable extinguishing

media

: 2-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28

T Cell Activator

None known. None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards arising from the chemical

: **2**-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28

T Cell Activator

No specific fire or explosion hazard.

In a fire or if heated, a pressure increase will occur

and the container may burst.

Hazardous thermal decomposition products : **2**-deoxyglucose (2-DG)

Decomposition products may include the following

materials: carbon dioxide

carbon monoxide

ImmunoCult™ Human CD3/CD28

T Cell Activator

Decomposition products may include the following

materials: carbon dioxide carbon monoxide nitrogen oxides phosphorus oxides

5.3 Advice for firefighters

Special protective actions

for fire-fighters

: 2-deoxyglucose (2-DG)

Promptly isolate the scene by removing all persons

from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or

without suitable training.

ImmunoCult™ Human CD3/CD28

T Cell Activator

Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or

without suitable training.

Section 5. Fire-fighting measures

Special protective equipment for fire-fighters

: **2**-deoxyglucose (2-DG)

Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

ImmunoCult™ Human CD3/CD28 T Cell Activator Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

Section 6. Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

: **2**-deoxyglucose (2-DG)

No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment.

ImmunoCult™ Human CD3/CD28 T Cell Activator

ImmunoCult™ Human CD3/CD28

No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment.

For emergency responders : **Z**-deoxyglucose (2-DG)

If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel". If specialized clothing is required to deal with the

spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

6.2 Environmental precautions

: **2**-deoxyglucose (2-DG)

T Cell Activator

Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers,

waterways, soil or air).

ImmunoCult™ Human CD3/CD28

T Cell Activator

Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has

caused environmental pollution (sewers,

waterways, soil or air).

6.3 Methods and materials for containment and cleaning up

Methods for cleaning up : 2-deoxyglucose (2-DG)

Move containers from spill area. Vacuum or sweep up material and place in a designated, labeled waste container. Dispose of via a licensed waste

disposal contractor.
ImmunoCult™ Human CD3/CD28 Stop leak if without i

T Cell Activator

Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

Date of issue: 04/29/2024 5/1

Section 7. Handling and storage

7.1 Precautions for safe handling

Protective measures

: **2**-deoxyglucose (2-DG)

Put on appropriate personal protective equipment (see Section 8).

ImmunoCult™ Human CD3/CD28 T Cell Activator

ImmunoCult™ Human CD3/CD28

Put on appropriate personal protective equipment (see Section 8).

Advice on general occupational hygiene : 2-deoxyglucose (2-DG)

Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8

for additional information on hygiene measures. Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any

incompatibilities

: 2-deoxyglucose (2-DG)

T Cell Activator

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use. Store in accordance with local regulations. Store in

original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

ImmunoCult™ Human CD3/CD28 T Cell Activator

7.3 Specific end use(s)

Recommendations

: **2**-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28

T Cell Activator

Industrial applications, Professional applications. Industrial applications, Professional applications.

Industrial sector specific solutions

: **2**-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 T Cell Activator

Not available. Not available.

Section 8. Exposure controls/personal protection

8.1 Control parameters

Occupational exposure limits

Ingredient name	Exposure limits	
2-deoxyglucose (2-DG) 2-deoxy-D-glucose	None.	

Biological exposure indices

No exposure indices known.

8.2 Exposure controls

Appropriate engineering controls

Environmental exposure controls

- : Good general ventilation should be sufficient to control worker exposure to airborne contaminants.
- : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

Individual protection measures

Hygiene measures

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period.

Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection

: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with sideshields.

Skin protection

Hand protection

: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

Body protection

: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection

: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection

: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Section 9. Physical and chemical properties and safety characteristics

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

Appearance

Physical state : 2-deoxyglucose (2-DG) Solid.

ImmunoCult™ Human CD3/CD28 Liquid. [Clear.]

T Cell Activator

Color : Z-deoxyglucose (2-DG) Not available.

ImmunoCult™ Human CD3/CD28 White.

T Cell Activator

Date of issue: 04/29/2024 **7/14**

Section 9. Physical and chemical properties and safety characteristics

: **2**-deoxyglucose (2-DG) Not available. Odor ImmunoCult™ Human CD3/CD28 Not available.

T Cell Activator

2-deoxyglucose (2-DG) Not available. Odor threshold

ImmunoCult™ Human CD3/CD28 Not available.

T Cell Activator

: **2**-deoxyglucose (2-DG) рH Not available.

ImmunoCult™ Human CD3/CD28 Not available.

T Cell Activator

Melting point/freezing point : **2**-deoxyglucose (2-DG) 146 to 147°C (294.8 to 296.6°F)

> ImmunoCult™ Human CD3/CD28 Not available.

T Cell Activator

Boiling point, initial boiling point, and boiling range

: **2**-deoxyglucose (2-DG) Not available. ImmunoCult™ Human CD3/CD28 Not available.

T Cell Activator

Flash point : 2-deoxyglucose (2-DG) Not applicable.

ImmunoCult™ Human CD3/CD28 Not available.

T Cell Activator

: **2**-deoxyglucose (2-DG) Not available. **Evaporation rate**

ImmunoCult™ Human CD3/CD28 Not available.

T Cell Activator

: **2**-deoxyglucose (2-DG) **Flammability** Not available.

ImmunoCult™ Human CD3/CD28 Not applicable.

T Cell Activator

Lower and upper explosion limit/flammability limit

Vapor pressure

2-deoxyglucose (2-DG) Not applicable. ImmunoCult™ Human CD3/CD28 Not available.

T Cell Activator

	Vapor Pressure at 20°C			Vapor pressure at 50°C		
Ingredient name	mm Hg	kPa	Method	mm Hg	kPa	Method
ImmunoCult™ Human CD3/CD28 T Cell Activator						
water	17.5	2.3	_	92.258	12.3	_

: 2-deoxyglucose (2-DG) Relative vapor density Not applicable. ImmunoCult™ Human CD3/CD28 Not available.

T Cell Activator

: **2**-deoxyglucose (2-DG) Not available. Relative density

ImmunoCult™ Human CD3/CD28 Not available.

T Cell Activator

Solubility(ies) Media Result 2-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28 T Cell

Activator

water Soluble

Partition coefficient: noctanol/water

2-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28

Not available. Not applicable.

Not available.

Soluble

T Cell Activator

Auto-ignition temperature Decomposition temperature

: 2-deoxyglucose (2-DG) Not applicable. : 2-deoxyglucose (2-DG) Not available. ImmunoCult™ Human CD3/CD28

T Cell Activator

Section 9. Physical and chemical properties and safety characteristics

Viscosity : **2**-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28

T Cell Activator

Not applicable.
Not available.

Not available.

Particle characteristics

Median particle size : **2**-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28 Not applicable.

T Cell Activator

Section 10. Stability and reactivity

10.1 Reactivity : **2**-deoxyglucose (2-DG)

No specific test data related to reactivity available

for this product or its ingredients.

ImmunoCult™ Human CD3/CD28

T Cell Activator

No specific test data related to reactivity available

for this product or its ingredients.

10.2 Chemical stability : **2**-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28

T Cell Activator

The product is stable. The product is stable.

10.3 Possibility of hazardous reactions

: 2-deoxyglucose (2-DG)

Under normal conditions of storage and use,

hazardous reactions will not occur.

ImmunoCult™ Human CD3/CD28

T Cell Activator

Under normal conditions of storage and use,

hazardous reactions will not occur.

10.4 Conditions to avoid : **2**-deoxyglucose (2-DG)

ImmunoCult™ Human CD3/CD28

T Cell Activator

No specific data. No specific data.

10.5 Incompatible materials : 2-deoxyglucose (2-DG)

z-deoxygidcose (z-bd)

ImmunoCult™ Human CD3/CD28

T Cell Activator

May react or be incompatible with oxidizing

materials.

May react or be incompatible with oxidizing

materials.

10.6 Hazardous

decomposition products

: 2-deoxyglucose (2-DG)

Under normal conditions of storage and use, hazardous decomposition products should not be

ImmunoCult™ Human CD3/CD28

T Cell Activator

Under normal conditions of storage and use, hazardous decomposition products should not be

produced.

Section 11. Toxicological information

11.1 Information on toxicological effects

Acute toxicity

Not available.

Irritation/Corrosion

Not available.

Sensitization

Not available.

Mutagenicity

Conclusion/Summary

: Not available.

Carcinogenicity

Conclusion/Summary : Not available.

Date of issue: 04/29/2024 9/14

Section 11. Toxicological information

Reproductive toxicity

Conclusion/Summary: Not available.

Teratogenicity

Conclusion/Summary: Not available.

Specific target organ toxicity (single exposure)

Not available.

Specific target organ toxicity (repeated exposure)

Not available.

Aspiration hazard

Not available.

Information on the likely

routes of exposure

: **Z**-deoxyglucose (2-DG) ImmunoCult™ Human CD3/CD28 Not available.
Not available.

T Cell Activator

Potential acute health effects

Eye contact : Z-deoxyglucose (2-DG) No known significant effects or critical hazards.

ImmunoCult™ Human CD3/CD28 No known significant effects or critical hazards.

T Cell Activator

Inhalation : Z-deoxyglucose (2-DG) No known significant effects or critical hazards.

ImmunoCult™ Human CD3/CD28 No known significant effects or critical hazards.

T Cell Activator

Skin contact : Z-deoxyglucose (2-DG) No known significant effects or critical hazards.

ImmunoCult™ Human CD3/CD28 No known significant effects or critical hazards.

T Cell Activator

Ingestion : Z-deoxyglucose (2-DG) No known significant effects or critical hazards.

ImmunoCult™ Human CD3/CD28 No known significant effects or critical hazards.

T Cell Activator

Symptoms related to the physical, chemical and toxicological characteristics

Eye contact : 2-deoxyglucose (2-DG) No specific data.

ImmunoCult™ Human CD3/CD28 No specific data.

T Cell Activator

Inhalation : Z-deoxyglucose (2-DG) No specific data.

ImmunoCult™ Human CD3/CD28 No specific data.

T Cell Activator

Skin contact : Z-deoxyglucose (2-DG) No specific data.

ImmunoCult™ Human CD3/CD28 No specific data.

T Cell Activator

Ingestion : Z-deoxyglucose (2-DG) No specific data.

ImmunoCult™ Human CD3/CD28 No specific data.

T Cell Activator

Delayed and immediate effects and also chronic effects from short and long term exposure

Short term exposure

Potential immediate : Not available.

effects

Potential delayed effects : Not available.

Long term exposure

Potential immediate : Not available.

effects

Potential delayed effects : Not available.

Date of issue: 04/29/2024 10/14

Section 11. Toxicological information

Potential chronic health effects

General : Z-deoxyglucose (2-DG) No known significant effects or critical hazards.

ImmunoCult™ Human CD3/CD28 No known significant effects or critical hazards.

T Cell Activator

Carcinogenicity : Z-deoxyglucose (2-DG) No known significant effects or critical hazards.

ImmunoCult™ Human CD3/CD28 No known significant effects or critical hazards.

T Cell Activator

Mutagenicity: **Z**-deoxyglucose (2-DG) No known significant effects or critical hazards.

ImmunoCult™ Human CD3/CD28 No known significant effects or critical hazards.

T Cell Activator

Reproductive toxicity: **Z**-deoxyglucose (2-DG)

No known significant effects or critical hazards.

ImmunoCult™ Human CD3/CD28 No known significant effects or critical hazards.

T Cell Activator

Numerical measures of toxicity

Acute toxicity estimates

N/A

Section 12. Ecological information

12.1 Toxicity

Not available.

12.2 Persistence and degradability

Not available.

12.3 Bioaccumulative potential

Not available.

12.4 Mobility in soil

Soil/water partition coefficient (Koc)

: Not available.

12.5 Other adverse effects : No known significant effects or critical hazards.

Section 13. Disposal considerations

13.1 Waste treatment methods

Disposal methods

: The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

Date of issue: 04/29/2024 **11/14**

Section 13. Disposal considerations

Disposal should be in accordance with applicable regional, national and local laws and regulations. Local regulations may be more stringent than regional or national requirements.

The information presented below only applies to the material as supplied. The identification based on characteristic(s) or listing may not apply if the material has been used or otherwise contaminated. It is the responsibility of the waste generator to determine the toxicity and physical properties of the material generated to determine the proper waste identification and disposal methods in compliance with applicable regulations.

Refer to Section 7: HANDLING AND STORAGE and Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION for additional handling information and protection of employees.

Section 14. Transport information

DOT / TDG / Mexico / IMDG / : Not regulated. **IATA**

Special precautions for user : Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the

event of an accident or spillage.

Transport in bulk according : Not available.

to IMO instruments

: Not listed

: Not listed

Not listed

: Not listed

Section 15. Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

: TSCA 8(a) CDR Exempt/Partial exemption: Not determined **U.S. Federal regulations**

Clean Air Act Section 112

(b) Hazardous Air

Pollutants (HAPs)

Clean Air Act Section 602

Class I Substances

Clean Air Act Section 602

Class II Substances

DEA List I Chemicals (Precursor Chemicals)

DEA List II Chemicals (Essential Chemicals)

: Not listed

SARA 302/304

Composition/information on ingredients

No products were found.

SARA 304 RQ : Not applicable.

SARA 311/312

2 deoxyglucose (2-DG) Classification ImmunoCult™ Human CD3/CD28 T Cell

Not applicable. Not applicable.

Composition/information on ingredients

No products were found.

State regulations

Massachusetts : None of the components are listed.

04/29/2024 Date of issue: 12/14

Section 15. Regulatory information

New York
None of the components are listed.
None of the components are listed.
Pennsylvania
None of the components are listed.

California Prop. 65

This product does not require a Safe Harbor warning under California Prop. 65.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

Inventory list

Australia : Not determined.

Canada : Not determined.

China : Not determined.

Japan : Japan inventory (CSCL): Not determined.

Japan inventory (ISHL): Not determined.

New Zealand : Not determined. **Philippines** : Not determined. Republic of Korea : Not determined. **Taiwan** : Not determined. **Thailand** : Not determined. **Turkey** : Not determined. **United States** : Not determined. **Viet Nam** : Not determined.

Section 16. Other information

Procedure used to derive the classification

Classification	Justification
Not classified.	

History

Date of issue/Date of : 04/29/2024

revision

Date of previous issue : 10/27/2023

Version : 3.1

Date of issue: 04/29/2024 **13/14**

Section 16. Other information

Key to abbreviations

: ATE = Acute Toxicity Estimate

BCF = Bioconcentration Factor

GHS = Globally Harmonized System of Classification and Labelling of Chemicals

IATA = International Air Transport Association

IBC = Intermediate Bulk Container

IMDG = International Maritime Dangerous Goods

LogPow = logarithm of the octanol/water partition coefficient

MARPOL = International Convention for the Prevention of Pollution From Ships, 1973

as modified by the Protocol of 1978. ("Marpol" = marine pollution)

N/A = Not available UN = United Nations

▼ Indicates information that has changed from previously issued version.

Notice to reader

Disclaimer: The information contained in this document is based on Agilent's state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.

Date of issue: 04/29/2024 14/14